Retatrutide Cloudy After Mixing? Vial Troubleshooting for Haze, Foam and Flakes

Mixed retatrutide needs to end up clear and colorless, and a vial that stays hazy isn't one to inject. If you find your retatrutide cloudy right after adding the water, swirl it gently and let it sit: a cap of foam is expected, and people often report a short haze that clears as the powder dissolves. Haze that won't clear, flakes, strings, a tint, or cloudiness that shows up days after a clear start are all signs the approved labels below treat as reasons not to use a vial.

Retatrutide is still investigational. Six Phase 3 trials have reported, but no approved version exists yet, and approved drugs are where a description of the product normally comes from. Lilly last said, on September 29, 2026, that it plans to submit retatrutide to the FDA in the first quarter of 2027 as a Biologics License Application (BLA). On October 2, 2026, the FDA decided that retatrutide is a drug, not a biological product, so an application would need to be filed under section 505 of the Federal Food, Drug, and Cosmetic Act. Lilly's appeal on that question is pending in the Seventh Circuit, and we found no ruling as of October 31, 2026.

So no label says what a retatrutide vial is supposed to look like, and the benchmarks here come from three approved labels: Egrifta WR (tesamorelin), a peptide powder people mix with bac water at home; Hospira's bacteriostatic water; and Lilly's Zepbound (tirzepatide). The mixing steps and dose math live in the reconstitution guide, and the rest of the series starts at how to take retatrutide; this page is for when the vial looks wrong.

What does reta look like before and after mixing?

If you've searched for what retatrutide looks like, the honest answer is that nobody official has said. Lilly's retatrutide FAQ, last updated October 2026, covers status, access, price and illicit products but says nothing about appearance, and as of October 2026 no Lilly document describes the powder or the liquid. The closest official descriptions come from approved drugs that share the job or the chemistry.

No one has published what a retatrutide powder cake is meant to look like, so its shape tells you little.

What color is retatrutide?

Colorless, once it's mixed. Lilly allows its tirzepatide liquid to run from colorless to slightly yellow, but that range belongs to Zepbound's tested formula. A home-mixed vial has no spec, so treat any tint as discoloration, which Hospira's bac water label says to check for before injecting anything mixed with it.

Why is my retatrutide cloudy?

When the haze appears tells you more than how it looks. FDA's draft guidance on visible particles lists what turns up in injectable drugs (metal, glass, dust, fiber, rubber, polymer, mold and precipitated breakdown products) and notes that particles formed when the drug itself comes out of solution can appear after a product leaves the factory and change in size or number during storage.

The first and third rows come from what people post. On peptide forums, people describe a haze in the first minutes after mixing that fades as the powder dissolves, and others describe a vial that went slightly cloudy in the fridge and cleared after a few minutes at room temperature. Forum posts, not a study.

The chemistry offers a clue. FDA's substance registry shows retatrutide carries a C20 fatty diacid, a fat chain attached to the peptide, and Zepbound's label shows tirzepatide carries the same kind of chain. Lilly ships tirzepatide with sodium chloride and a phosphate buffer at pH 6.5 to 7.5. Bac water has no buffer, and Hospira's label puts its pH at 5.7, anywhere from 4.5 to 7.0.

Our read: a fat-tagged peptide dropped into unbuffered, slightly acidic water is a plausible reason for the haze people describe. Nobody has published how retatrutide behaves in bac water, though, so that's a guess about cause and never a reason to inject a cloudy vial.

Is cloudy retatrutide safe to inject?

No, and you can't tell from the outside which kind of cloudy you have. The haze could be clumped drug, microbes or particles that came with the vial, and a syringe draws up all of them. Egrifta WR's and Zepbound's instructions both say not to use medicine that's cloudy, discolored or has particles, and neither offers a way to rescue it.

FDA's particle guidance lists what contaminated injections have caused in published case reports, including inflammation, small lumps of immune cells (granulomas) and infections at the injection site, with worse harm when particles reach the blood. Particles generally cause fewer problems in shots under the skin than in shots into a vein, the guidance says.

FDA's 2014 guidance on immune reactions to protein drugs adds a second concern: protein clumps (aggregates), from pairs of molecules up to visible specks, have been recognized as a possible trigger of immune responses for more than half a century, including antibodies that can blunt the drug. In Zepbound's trials, injection site reactions hit 11.3% of people who developed antibodies to tirzepatide, against 1% of those who didn't. Both are class evidence, not retatrutide data.

Clumping changes the dose too. Drug that has settled into flecks isn't spread evenly through the liquid, so the units you draw no longer hold what the math says they do.

Why won't my retatrutide dissolve?

Give it time before you change anything. Egrifta WR's instructions allow tesamorelin only a few seconds of rest before it must be clear, while forum posts describe retatrutide haze that takes minutes to clear. What the approved instructions do tell you:

1. Swirl the vial in a circle to mix the powder and liquid. Don't shake it (Egrifta WR).
2. Let it rest so the foam separates (Egrifta WR).
3. Hold it to the light against a dark background, then a light one, the contrast FDA's guidance describes for manual particle checks.
4. If it's still hazy or has flecks after a long rest, stop there and don't inject it.

Two fixes people reach for cause their own trouble. Adding more water changes the strength of the whole vial, so every dose after that needs new math. A 10 mg vial planned at 1 mL holds 1 mg in every 10 units (the 10 mg vial page has the full table). Top it up to 2 mL and the same 2 mg dose takes 40 units instead of 20.

If you've already added water, put your vial size, the total water now in it and your dose in here to see the new unit count.

The other fix, discussed on forums and seller blogs, is swapping the liquid for acidified (acetic acid) water. Hospira's label warns that some drugs don't mix well in bac water or with benzyl alcohol, and no one has published which liquid retatrutide needs. If a vial won't dissolve, take it up with whoever sold it. If you did add water, the dose calculator above redoes the units, and the reconstitution calculator works out how much water gives a set unit count on a fresh vial.

Foam and air bubbles in a vial, syringe or pen

Foam and bubbles are air. FDA's particle guidance defines particles as undissolved matter "other than gas bubbles", so a bubble on its own isn't a quality problem.

• In a freshly mixed vial, a layer of foam is expected. Egrifta WR's instructions say to let the vial rest until the foam separates and the liquid is clear.
• In a syringe, bubbles take up room meant for the dose. Zepbound's vial instructions say to tap the syringe gently so they rise, then push the plunger to the dose line.
• In a pen, Lilly's Zepbound single-dose pen instructions say air bubbles are normal. For the multi-dose KwikPen, Lilly says to prime before every weekly injection: tap the cartridge so bubbles collect at the top, then push out a drop.

Flecks or a film left behind once the foam goes are a particle problem, and the cloudy rules apply. A pen has no mixing step, so the cartridge window is the only look you get; our reta pen guide covers priming.

What a clear vial can't tell you

Clear, colorless liquid rules out some problems and says nothing about what's in the vial or how much. In September 2026, Australia's TGA tested an unmarked vial sold as retatrutide after a person was treated in hospital for uncontrollable vomiting and a torn esophagus. It held no retatrutide at all, and semaglutide at about 8 times the level in approved semaglutide products. In June 2026, Victoria's Chief Health Officer linked six cases of acute liver injury to products labeled Retatrutide, Reta, R-10 and R-20, possibly from a contaminant, and said all such products are at risk.

That's why people weighing retatrutide for sale listings look for a third-party test report (our testing guide covers how to read one) tied to the batch number on that exact vial, covering identity, purity, amount and, where offered, endotoxin or sterility. Even a good report describes the powder on the day it was tested, not the liquid weeks after mixing. Lilly's October 2026 FAQ says retatrutide "has not been reviewed or approved by the FDA or any regulatory agency in the world, and no one can legally sell it for human use," and that illicit products may hold unknown ingredients, harmful contaminants, too much or too little active ingredient, or the wrong ingredient entirely. The legal status page covers what that means for buyers.

Our read: a look can fail a vial but can't pass one. Of the 7 problems in that table, a look fully catches 2 and partly catches a third; the other 4 need a lab.

When to throw a vial out and when to get help

Throw the vial out if any of these is true:

• It's still cloudy or has flecks after a gentle swirl and a long rest.
• It was clear and later turned cloudy, flaky, stringy or tinted.
• You can see fibers, glass or rubber bits.
• It froze (Zepbound's label says not to use it if frozen), or it arrived warm. FDA advises against using any injectable GLP-1 drug that arrives warm or without enough cooling.
• It's more than 28 days since the first use, the limit FDA recommends for multi-dose vials, even with liquid left.

Fridge temperatures and what to do with a vial left out overnight are on the retatrutide storage page, and injection site care is covered in how to inject retatrutide.

If a vial fails the look test, photograph the liquid, the label and the batch number before you dispose of it. Victoria's alert asks doctors to get a sample or photos of the product and packaging where they can, so if you feel unwell, take the vial or the photos with you.